Warren Foust on direct-to-consumer marketing
From OIS Podcast Ep #367: A Fast, Fun Future, with Warren Foust and Magda Michna, PhD, Staar Surgical · · OIS: Ophthalmology Innovation Source
“This is really the only company that's providing this avenue by which we're trying to help our refractive surgeons grow their practices and DTC is advertising is expensive and it's complicated. We have an amazing group of marketers which have done a great job under the leadership of David Kormanski to guide us there and so make sure that we're using dollars in the right way.”
On , Warren Foust, President & Chief Operating Officer at STAAR SURGICAL CO, spoke about direct-to-consumer marketing during OIS Podcast Ep #367: A Fast, Fun Future, with Warren Foust and Magda Michna, PhD, Staar Surgical on OIS: Ophthalmology Innovation Source.
About Warren Foust
Warren Foust, who was named President and Chief Operating Officer of Staar Surgical in 2023, discussed the company's growth and strategy on the OIS Podcast in September 2023. He stated that the company is experiencing double-digit growth in every market and described the company's values as including "empowerment of our people, driving a fast sense of execution, and fun." Foust noted that Staar Surgical handles its direct-to-consumer advertising in-house, citing a campaign with Nick Jonas and a subsequent partnership with all three Jonas Brothers to support their tour. He said the company asks for volume commitments from physician partners because the technology "warrants it" and that Staar Surgical runs national campaigns to drive traffic to customers. Foust described his move from Johnson & Johnson to Staar Surgical as "hard from the perspective of leaving" but "easy from the standpoint that STAAR is an amazing company with a trajectory for explosive growth." He said the company provides "fast start" training programs for surgeons and customizes solutions for different types of customers, including independent practices and large systems. Foust also stated that when the company enters a new market, it sees "incredible adoption" and reported a 99.4 percent patient satisfaction rate for the EVO ICL procedure.